|
|
|
|
|
|
|
M T W Thu F |
|
15 October, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life sciences investor OrbiMed just closed $3 billion across two new funds for drug development, medical devices, diagnostics and health tech. Nearly two-thirds of the new money is earmarked for the US and Europe, and the rest is Asia focused. Max Gelman has the details. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
OrbiMed, one of the biggest life science investors in the world, has raised $3 billion across two new funds. OrbiMed’s 10th private equity fund in... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Osivax’s lead flu vaccine has flopped in a mid-stage trial. But the French biotech still holds out hope for the program, and plans to combine... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about ImmunityBio, Modus Therapeutics and Hyperway Pharmaceutical. AstraZeneca strikes AI drug discovery deal with insitro: The pharma giant will paythe California-based company... | |
|
|
|
|
|
